Comparison of a Stool Antigen Test and Serology for the Diagnosis of Helicobacter pylori Infection in Mass Survey
Open Access
- 11 March 2009
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 14 (2), 87-90
- https://doi.org/10.1111/j.1523-5378.2009.00672.x
Abstract
Background: Serum antibody to Helicobacter pylori is tested in mass screening for gastric cancer along with the level of serum pepsinogens (PG) I and II. Recently, stool antigen tests have been developed as a new non‐invasive test. We examined H. pylori infection by both serology and stool antigen test in a mass survey and compared the results to estimate applicability of stool antigen test for mass survey. Methods: A total of 994 healthy adults who received mass survey in April 2005 were tested. There were 379 men and 615 women, and the mean age was 57.7 years old. Stool samples were used to measure a H. pylori‐specific antigen by enzyme immunoassay. Serum samples were tested for the prevalence of IgG antibody to H. pylori, and the level of PGs I and II was also measured to determine the presence of atrophic gastritis. Results: Infection of H. pylori was defined as positive 61.4% and 56.4% by serology and stool antigen test, respectively. The concordance of both tests was not affected by gender and age of the subjects but difference was seen in subjects with atrophic gastritis. In particular, positivity of stool antigen test (81.8%) was significantly lower than that of serology (88.7%, p < .05) in 303 subjects with severe atrophic gastritis. Conclusions: Stool antigen test, which detects present but not previous infection of H. pylori, would be applicable to diagnose H. pylori infection in mass survey. Usefulness of stool antigen tests for the screening of gastric cancer should be examined.Keywords
This publication has 15 references indexed in Scilit:
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- Helicobacter pylori eradication prevents the development of gastric cancer - results of a long-term retrospective study in JapanAlimentary Pharmacology & Therapeutics, 2007
- Effect of eradication of Helicobacter pylori on genetic instabilities in gastric intestinal metaplasiaAlimentary Pharmacology & Therapeutics, 2006
- Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection before and after eradication therapyAlimentary Pharmacology & Therapeutics, 2006
- The Serum Pepsinogen Test as a Predictor of Gastric CancerAmerican Journal of Epidemiology, 2006
- Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophyAlimentary Pharmacology & Therapeutics, 2005
- Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort studyGut, 2005
- Evaluation ofHelicobacter pyloristool antigen test before and after eradication therapyJournal of Gastroenterology and Hepatology, 2003
- Helicobacter pyloriInfection and the Development of Gastric CancerThe New England Journal of Medicine, 2001
- Clinical Application of Serum Pepsinogen I and II Levels for Mass Screening to Detect Gastric CancerJapanese Journal of Cancer Research, 1993